Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

For patients with newly diagnosed brain metastases without a history of seizure activity, do you routinely start anti-seizure medication?

5
1 Answers

Mednet Member
Mednet Member
Neurology · Wake Forest School of Medicine

This is a common clinical question that has been repeatedly explored in meta-analyses and clinical guidelines. Consistently, there's no evidence to support primary prophylaxis for seizures in patients with brain tumors including brain metastases. In summary, the data does not support the routine use...

What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Brigham and Women's Hospital

Most relapses from complete remission in patients with diffuse large B-cell lymphoma are symptomatic. I am aware of no evidence that surveillance leads to the diagnosis of asymptomatic relapses that are more likely to respond to salvage therapy. My own concern about frequent surveillance is the adve...

What is your approach to optimizing pre-operative hemoglobin in patients with sickle cell disease?

1 Answers

Mednet Member
Mednet Member
Hospital Medicine · University of Iowa Hospitals and Clinics

Unfortunately, I am not aware of a more comprehensive document than the ASH guidelines. These are what I use to define my default management strategy, often in coordination with our dedicated hematology consult subspecialist service.

Would you consider a BRCA carrier patient for kidney transplantation?

2
5 Answers

Mednet Member
Mednet Member
Nephrology · UCSF

I would certainly consider a potential recipient who is a BRCA carrier. Would involve genetic counseling as well as informed consent regarding the risk of malignancy post-transplant. The mortality risk, depending on co-morbidities, of remaining on dialysis is high and should certainly be considered ...

How would you evaluate a patient with an isolated high RBC count but with a normal hemoglobin and hematocrit?

2 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

My first question would be, how long has the elevated red cell count been present? I ask this because, in a study of 10,000 individuals, erythrocytosis was initially found in 88 but after a year only 11 still had this finding (Ruggeri et al., PMID 13679323). If therefore, the observation is recent, ...

What are your top takeaways in Thoracic Cancers from ASCO 2025?

1
12 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Michigan Medical School

More presentations that were interesting for the future, than immediately impactful in thoracic oncology this year at the ASCO meeting. Immediately impactful: 8006 and 8008 – Both in SCLC. 8006- IMforte trial suggesting improvement in survival with the addition of maintenance lurbinectedin to atezo...

Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Nebraska Medical Center

The IMforte trial specifically excluded these patients, a major drawback of this trial in my opinion. It may not be unreasonable to consider it, especially if the patient has a good performance status and is motivated to get it. However, I would discuss the pros and cons and make it clear that this ...

Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Loyola University Medical Center

I agree with the answer here by Dr. @Dr. First Last. There are a lot of nuances, though. In regard to giving the vaccine safely and effectively, the best strategy is not to wait until patients have multiple relapses and are on bispecific therapy to vaccinate. Given the recent outbreaks of measles, i...

Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Loyola University Medical Center

I agree with the answer here by Dr. @Dr. First Last. There are a lot of nuances, though. In regard to giving the vaccine safely and effectively, the best strategy is not to wait until patients have multiple relapses and are on bispecific therapy to vaccinate. Given the recent outbreaks of measles, i...

Would you extend the duration of anticoagulation in patients with a provoked DVT, but evidence of residual clot at 3 months?

9
3 Answers

Mednet Member
Mednet Member
Hematology · Gundersen Health

This is a really interesting discussion. I do tend to get Dopplers at the end of the anticoagulation treatment period, but only to assess the new baseline and to help decision-making in the future if they develop new symptoms and have another Doppler. I find this to be very helpful to understand if ...